Genetic polymorphisms in early-onset myocardial infarction in a sample of Iraqi patients: a pilot study

Ameen M. Mohammad1*, Galawezh O. Othman2, Chiman H. Saeed3, Sarah Al Allawi4, George S. Gedeon5, Shatha M. Qadir6 and Nasir Al-Allawi7

Abstract

Objectives: Early-onset myocardial infarction constitutes nearly one third of cases of myocardial infarction among Iraqis, which is rather higher than the proportions reported in many Western countries. Thus this study was initiated to investigate the role of some genetic polymorphisms, as well as acquired risk factors in this condition.

Results: A total of 102 Iraqi patients with first myocardial infarction aged 50 years, and 77 matched controls were enrolled. The DNAs of participants were screened for nine polymorphisms, namely: β-Fibrinogen (−455G > A), Factor XIII (V34L), Plasminogen Activator inhibitor-1 (PAI-1, 4G/5G), Human Platelet Antigen-1 (HPA1a/b), 5,10-Methylene-tetrahydrofolate Reductase MTHFR (C677T) and MTHFR (A1298C), Angiotensin-Converting Enzyme (ACE) 287 bp insertion/deletion (I/D), Apolipoprotein-B (ApoB: R3500Q), and Apolipoprotein-E (Apo E: E2/E3/E4), using PCR and reverse hybridization technique. Among traditional risk factors, univariate analysis revealed that smoking (OR 2.86 [95%CI 1.53–5.34]), hyperlipidemia (OR 5.23 [95%CI 2.66–10.29]), and diabetes mellitus (OR 4.05 [95% CI 1.57–10.41]) were significantly higher among patients compared to controls (P<0.001, <0.001 and 0.002 respectively), while none of the nine genetic polymorphisms reached significance. Multivariate Logistic regression, however, revealed that only smoking and hyperlipidemia retained significance (P of < 0.001 each). The need to initiate further studies on larger cohorts is paramount to understand the higher than expected frequency of early-onset myocardial infarction in our population.

Keywords: Premature myocardial infarction, MTHFR, ACE, PAI-1, HPA-1, β-fibrinogen, Risk factors, Iraq

Introduction

Myocardial infarction (MI) is one of the leading causes of morbidity and mortality worldwide, whether in developed or developing countries [1]. Among Iraqis, early-onset myocardial infarction constitutes up to one third of all MI cases, well exceeding the 5–10% reported in developed countries [2–4]. The fact that there is documented familial clustering of MI cases suggests that in addition to the conventional acquired risk factors, there is an element of genetic predisposition, that may presumably be more relevant to younger patients [5, 6]. Throughout the past few decades a number of these genetic factors have been investigated by various researchers, but with conflicting results [5–9]. In the current study we assessed the roles of nine polymorphisms that may be linked to coronary artery disease. Among these polymorphisms are those at the Methylenetetrahydrofolate Reductase gene (MTHFR C677T and A1298C), which lead to a deficiency of this key enzyme with consequent hyperhomocysteinemia. The latter has been linked to arterial thrombosis [10]. Another polymorphism is factor XIII Val34Leu,
which results in accelerated conversion of factor XIII to activated FXIIIa, and altered cross-linked fibrin clot structure [11]. While, β-Fibrinogen G -455 A involves the β-polypeptide chain of fibrinogen and leads to increased fibrinogen concentration, presumably conferring increased susceptibility to coronary heart disease [12]. Plasminogen activator inhibitor type 1 (PAI-1) is important in the regulation of endogenous fibrinolysis, and an increase in its circulating levels may be associated with the progression of atheromas and thrombosis [13]. A single nucleotide polymorphism of the GPIIIa gene causes Leu33Pro changing the human platelets antigen 1(HPA1) from 1a to 1b, with altered antigenic properties and an associated increase in platelet reactivity, thus fostering a prothrombotic state [14]. On the other hand, a polymorphism in the angiotensin-converting enzyme (ACE) gene characterized by insertion (I) or deletion (D) within its intron 16 has been described, with the D allele being associated with higher ACE levels and possible increased risk of coronary artery disease [15]. Apolipoprotein E (ApoE) is a glycoprotein that serves as a legend for cell surface receptor uptake of chylomicrons and Very Low Density Lipoprotein (VLDL) in the liver and extrahepatic cells [16]. ApoE polymorphism includes three isoforms E3, E2 and E4, among which the latter was more likely to be linked with coronary heart disease risk [17]. Moreover, Apolipoprotein B-100 (ApoB -100) is a component of the circulating low density lipoprotein (LDL) and serves as a legend for its uptake by the liver LDL receptors [18], and an arginine to glutamine change at codon 3500 of the ApoB-100 is a well-known genetic cause of hypercholesterolemia and premature atherosclerosis [19].

The current study is a pilot study focused on a population of young Iraqi adults with documented first incident of acute MI, to determine whether certain genetic polymorphisms are significant contributors to MI risk in this population.

Main text
Participants
A total of 179 participants who were 50 years or younger were enrolled. They included 102 patients with history of a single documented myocardial infarction visiting two cardiac centers in Erbil and Duhok-Iraq, together with 77 age and sex matched controls visiting the outpatient clinic at Azadi teaching hospital – Duhok-Iraq, but with no history of coronary artery disease or stroke.

Methodology
All patients had their records reviewed, and a detailed history and clinical examination were undertaken in each. They also had the appropriate laboratory investigations. The patients’ clinical examination and records were particularly scrutinized for the main traditional cardiovascular risk factors, namely smoking, hypertension, diabetes mellitus, and hyperlipidemia. Hypertension was defined as blood pressure in excess of the threshold of 140/90 mm Hg, and/or antihypertensive therapy use. Diabetes mellitus was defined as fasting serum glucose in excess of 126 mg/dL on two occasions, and/or anti-diabetic therapy use. Hyperlipidemia, and for the purposes of this study, was defined as a fasting serum cholesterol in excess of 200 mg/dL, and/or serum triglyceride in excess of 150 mg/dL, and/or the use of statins [20–22].

All patients and controls had their DNA extracted from EDTA blood by Qiagen QIAmp Kit (Qiagen, Germany). The extracted DNA was then amplified by multiplex Polymerase Chain Reaction (PCR) and reverse hybridized to detect the following mutations: β-Fibrinogen (-455 G > A), Factor XIII (V34L), Plasminogen Activator Inhibitor-1 (PAI-1, Serpin E1, 4G/5G), Human Platelet Antigen-1 (HPA1a/b; GplIIa; integrin beta 3 L33P), 5,10-Methylenetetrahydrofolate reductase MTHFR (C677T) and MTHFR (A1298C), Angiotensin-Converting Enzyme (ACE) 287 bp insertion/deletion (I/D), Apolipoprotein-B (ApoB: R3500Q), and Apolipoprotein-E (ApoE: E2/E3/E4), using the CVD StripAssay according to the manufacturer’s instructions (ViennaLab Diagnostics GmbH, Austria).

Statistical analysis
Data were evaluated using SPSS software (release 20; SPSS inc., Chicago, IL, USA). Univariate analysis utilized the student t-test for continuous variables, and the Chi square test for categorical ones, as appropriate. For associations with a P value < 0.25 by univariate analysis, multivariate analysis using logistic regression was used to evaluate the significance of the presence of at risk alleles and traditional risk factors, in patients compared to controls, with age and sex as covariates. A P value of <0.05 was considered significant.

Results and discussion
Among the 102 patients enrolled, the most frequent traditional risk factors encountered were hyperlipidemia and smoking, followed by hypertension, and diabetes mellitus (Table 1). Univariate analysis revealed that all these four risk factors had higher frequencies among patients compared to controls, and this was significant in all, except for hypertension. Multivariate analysis, on the other hand, asserted the significance of both smoking and hyperlipidemia (P < 0.001 each). These observations are consistent with many previous studies worldwide on MI in young adults. In the INTERHEART study, which is a case control study, including around 15,000 patients and 15,000 controls from 52 countries, Yusuf and coworkers.
documented that smoking, hyperlipidemia, hypertension and diabetes had a greater relative effect on the risk of acute myocardial infarction in younger rather than older individuals [1]. Other studies reported that smoking is particularly more frequently associated with MI among young adults in various populations including Iranians, Americans, Omanis, Turks, Arabs in UAE and Indians [3, 23–27]. Similarly, hyperlipidemia has been documented as a highly important risk factor in young MI patients in several studies from various populations, including Indians, Arabs, Americans and West Europeans [1, 24, 26, 28].

Among the nine polymorphism screened for by the current study, the highest allele frequencies were those for ACE (D allele), PAI (4G allele) and MTHFR 1298 (C allele) and MTHFR 677 (T allele). The ApoB R3500Q polymorphism was not detected in any of the patients or controls. The allele frequencies for majority of these polymorphisms were rather similar in patients and controls, except for β Fibrinogen -455 A allele which was more frequent among controls, and the HPA1 (1b allele) which was higher in patients (Table 2). Neither the latter two polymorphisms nor any of the other seven were significantly different between patients and controls, whether by univariate or multivariate analysis (Tables 2 and 3).

### Table 1  The frequencies of traditional risk factors in 179 enrolled patients and controls

| Parameter                  | Patients no (%) | Controls no. (%) | P value | Odds ratio (95% confidence interval) |
|----------------------------|-----------------|------------------|---------|-------------------------------------|
| Number                     | 102             | 77               | –       | –                                   |
| Age mean (SD)              | 42.4 (6.19)     | 41.6 (7.09)      | 0.448   | –                                   |
| Sex (no. males/no. females)| 77/25           | 57/20            | 0.823   | –                                   |
| Smoking                    | 56 (54.9)       | 23 (29.8)        | <0.001  | 2.86 (1.53–5.34)                    |
| Hypertension               | 37 (36.3)       | 20 (26.0)        | 0.143   | 1.62 (0.85–3.11)                    |
| Diabetes mellitus          | 26 (25.5)       | 6 (7.8)          | 0.002   | 4.05 (1.57–10.41)                   |
| Hyperlipidemia             | 59 (57.8)       | 16 (20.8)        | <0.001  | 5.23 (2.66–10.29)                   |

### Table 2  The genotypes and allele frequencies of nine polymorphisms screened for among patients and controls (P values are for allele frequencies)

| Mutation                         | Patients | Controls | P value | Allele frequency | Allele frequency |
|----------------------------------|----------|----------|---------|------------------|------------------|
| MTHFR C677T                      | 13       | 12       | 0.554   | 56.0             | 56.0             |
| MTHFR A1298C                     | 20       | 16       | 0.503   | 34.3             | 32.0             |
| FXIII Val34Leu                   | 4        | 1        | 0.952   | 76.0             | 55.0             |
| β Fibrinogen − 455 G > A        | 2        | 6        | 0.159   | 65.0             | 44.0             |
| Plasminogen activator inhibitor (4G) | 22   | 18       | 0.758   | 28.0             | 20.0             |
| Human Platelet Antigen 1 (HPA1) 1b | 4    | 1        | 0.07    | 71.0             | 62.0             |
| Angiotensin-converting Enzyme (ACE D) | 37  | 21       | 0.439   | 22.0             | 16.0             |
| Apo B                            | 0        | 0        | –       | 0.0              | 0.0              |
| Apo E allele (E4)                | 1        | 0        | 0.854   | 92.0             | 68.0             |

### Table 3  Multivariate logistic regression in a model including variables with P <0.25 by univariate analysis, with age and sex as covariates

| Risk factor                  | B     | SE    | P value | Exp (B) | 95% CI for Exp (B) |
|------------------------------|-------|-------|---------|---------|---------------------|
| Fibrinogen GA                | −1.641| 0.942 | 0.082   | 0.194   | 0.03–1.23           |
| Fibrinogen AA                | −1.734| 0.966 | 0.073   | 0.177   | 0.03–1.17           |
| HPA-1 1a/1b                  | 1.620 | 1.274 | 0.204   | 5.055   | 0.42–61.43          |
| HPA-1 1b/1b                  | 1.034 | 1.309 | 0.429   | 2.814   | 0.22–36.58          |
| Smoking                      | 1.438 | 0.404 | <0.001  | 4.214   | 1.91–9.30           |
| Hypertension                 | 0.021 | 0.397 | 0.959   | 1.021   | 0.47–2.22           |
| Diabetes mellitus            | 0.934 | 0.554 | 0.092   | 2.544   | 0.86–7.53           |
| Hyperlipidemia               | 1.469 | 0.391 | <0.001  | 4.347   | 2.02–9.36           |
Among the genetic polymorphisms investigated in the current study, two were in the MTHFR gene, namely: C677T and A1298G. Neither was found to be associated with increased risk of MI. This is contrast to an earlier study from the Iraqi population linking C677T to another type of arterial thrombosis, namely Ischemic stroke [29], and is also in contrast to studies from Turkey and Greece, suggesting that C677T mutation may be a risk factor for premature MI [30, 31]. However, our observations are consistent with other studies from Greece and South Africa which failed to document any associations [32, 33].

In the current study the allele frequency of FXIII Val-34Leu polymorphism was not significantly different between patients and controls. This is consistent with some European studies on premature MI [34, 35], but is contrary to others, including a meta-analysis suggesting that it had an unexplained protective role in young MI patients as compared to healthy controls [36–38].

Studies on the association of β fibrinogen G-455A polymorphism with MI had revealed conflicting results. So that while a recent meta-analysis on Asian patients had linked it to a slightly increased risk [39], others failed to show such a link among Italian patients [40]. Moreover, and contrary to the latter two observations, a study on young Greek MI patients documented a protective effect of this polymorphism [41], which is consistent to some extent with our own observations, where both AA and AG genotypes conferred apparently protective effects by multivariate analysis, though this just failed to reach significance (Table 3). Such findings are unexpected, since this polymorphism is associated with increased fibrinogen, and thus a presumed increased risk of MI. One possible explanation may be that β fibrinogen G-455A polymorphism is in linkage disequilibrium with some other unknown polymorphism that confers a protective role. Further studies including larger numbers of patients are needed to address this issue.

A single insertion/deletion mutation in the promoter sequence of the PAI-1 gene at position -675 (4G/5G polymorphism) had been linked to PAI-1 levels with the 4G being associated with a higher enzyme level than the 5G allele [42, 43]. Nikolopoulos and coworkers in a meta-analysis demonstrated that the 4G allele is associated with a slightly increased risk of MI [44]. In the current study, and contrary to the latter meta-analysis, but similar to studies from Egyptian, young Italian and Finnish patients, the 4G allele was not associated with such an increased risk [7, 45, 46].

The results of studies on association of HPA 1b with premature MI are conflicting, so that while some studies dispute an association, others confirm it [47–49]. It is worth noting that the current study revealed that patients had a higher frequency of HPA 1b allele and were more likely to be homozygous to it than controls, but this did not reach significance (Tables 2 and 3).

Studies on Asian, Caucasian, as well as some North African populations documented that the ACE D allele is an MI risk factor [50–52]. The current study failed to document a significant association between ACE D allele and MI, which is consistent with studies from neighboring Iran, where it was concluded that ACE D allele is not an MI risk factor [53].

In relevance to APO E polymorphism, the current study did not show a significant difference between allele frequencies of E4 allele between patients and controls, which is consistent with a large meta-analysis including more than 22 000 British patients which also failed to document such a link [54]. While in relevance to APO B 100 polymorphism, the current study did not show any carriers of this mutation among 179 patients and controls enrolled, which is similar to studies from neighboring Turkey and Saudi Arabia where this mutation is also absent [55, 56]. This is in contrast to that seen among Caucasians, where this polymorphism is rather frequent and is an important contributor to MI risk [19].

In conclusion, it appears based on this pilot study that among young Iraqis with MI, traditional factors seem to be the main culprits related to risk, while none of the nine genetic polymorphisms studied were associated with increased risk.

Limitations
The main limitation of the current study, as with all pilot studies is related to numbers of enrolled individuals, and more patients and controls would certainly have led to more informative results. However, certain important observations requiring scrutiny emerged, including a possible protective role for β fibrinogen G-455A polymorphism, and a possible increased risk of premature MI in association with HPA-1b polymorphism.

Abbreviations
ACE: Angiotensin-Converting Enzyme.; ApoB: Apolipoprotein B.; ApoE: Apolipoprotein E.; HPA: Human Platelet Antigen.; LDL: Low-Density Lipoprotein.; MI: Myocardial infarction.; MTHFR: Methylene tetrahydrofolate reductase.; PAI: Plasminogen Activator Inhibitor.; PCR: Polymerase Chain reaction.; VLDL: Very Low-Density Lipoprotein.

Acknowledgements
None to report.

Authors’ contributions
AMM contributed to concept and design, clinical assessment of patients, and writing; GOO: concept; patients’ assessment, molecular workup, and writing; CHS: molecular workup; SA: clinical assessment, analysis of data and writing; GSG: analysis of data and writing; SMQ: molecular workup; NA: concept and design, molecular workup, analysis of data and writing. All authors approved the final version of the manuscript.
References

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part 1: General considerations, the epidemiologic transition, risk factors, and the impact of urbanization. Circulation. 2001;104:2746–56.

2. Mohammad AM, Jehangeer HI, Shaikow SK. Prevalence and risk factors of premature coronary artery disease in patients undergoing coronary angiography in Kurdistan Iraq. BMC Cardiovasc Disord. 2015;15:155.

3. Doughty M, Mehta R, Bruckman D, Das S, Karavite D, Tsi T, et al. Acute myocardial infarction in the young—the university of Michigan experience. Am Heart J. 2002;143(1):56–62.

4. Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction. Blood. 1999;94(1):46–51.

5. Sakowicz A, Fendler W, Lelonek M, Sakowicz B, Pietrucha T. Genetic polymorphisms and the risk of myocardial infarction in patients under 45 years of age. Biochem Genet. 2012;51(3–4):230–42.

6. Sharma M, Ganguly NK. Premature coronary artery disease in Indians and its associated risk factors. Vasc Health Risk Manag. 2008;4(3):217–25.

7. Yamac AH, Uysal O, Ismaeloglu Z, Ertürk M, Celikten M, Bacakasiz A, et al. Premature Myocardial infarction: Genetic variation in SR1 affects disease susceptibility. Cardiol Res Pract. 2019;2019:8921806.

8. Andrews E, León M, Cordero A, Botaya RM, Vavoulis P, Pavlakis G, Travlou A, et al. Premature Myocardial Infarction: Genetic Variation in SR1 Affects Disease Susceptibility. Cardiol Res Prat. 2019;2019:8921806.

9. Al-Allawi N, Avo A, Jubrael J. Methylene tetrahydrofolate reductase C677T polymorphism among Iraqi patients with ischemic stroke. Neurol India. 2009;57:631–5.

10. Gülec S, Aras O, Akar E, Tutur E, Omurlu K, Avci F, et al. Methylenetetrahydrofolate reductase gene polymorphism and the risk of premature myocardial infarction. Atherosclerosis. 2008;200(1):115–20.

11. Ranjith N, Begoraro RJ, Rom L. Risk factors and methylenetetrahydrofolate reductase gene polymorphisms in a young South African Indians born population with acute myocardial infarction. Cardiovasc J Afr. 2003;14(3):127–32.

12. Efeyciou C, Antoniades L, Makri L, Koumas L, Costeas PA, Kyriakou E, et al. Homocysteine levels and MTHFR mutations in young patients with acute myocardial infarction: a case control study. Hellenic J Cardiol. 2012;53(3):189–94.

13. Ambroziauskas M, Kuryłowicz A, Buda A. Increased coagulation factor XIII activity but not genetic variants of coagulation factors is associated with myocardial infarction in young patients. J Thromb Thrombolysis. 2019;48(3):519–27.

14. Song C, Burgess S, Eicher JD, O’Donnell CI, Johnson AD. Causal effect of plasminogen activator Inhibitor Type 1 on coronary heart disease. J Am Heart Assoc. 2017;6:e004918.

15. Pagani G, Pereira JVP, Stolol JK, Beck A, Scharf RE, Gokalie H. The human platelet antigen-1b (Pro3) variant of alpha2B, allosterically shifts the dynamic conformational equilibrium of this integrin toward the active state. J Biol Chem. 2018;293(1):4830–44.

16. Samani NJ, Thompson JR, O’toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation. 1996;94:708–12.

17. Xu H, Li H, Liu J, Zhu D, Wang Z, Chen A, et al. Meta-analysis of apolipoprotein E gene variants and risk of coronary heart disease: a meta-analysis. Biomed Res Int. 2016;2016:3912175.

18. Pasternak RC. Report of the adult treatment panel III: the 2001 national cholesterol education program guidelines on the detection, evaluation and treatment of elevated cholesterol in adults. Cardiol Clin. 2003;21(3):393–89.

19. Shemirani H, Sepahram KH. The relative impact of smoking or hyper-tension on severity of premature coronary artery disease. Irnana Red Crescent Medical Journal. 2007;9(4):177–81.

20. American Diabetes Association. Standards of medical care in Diabetes-2010. Diabetes Care. 2010;33(Suppl 1):S1–61.

21. Obardian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC7 report. JAMA. 2003;289(19):2560–72.

22. Prashanth P, Kadhim S, Ibrahim A-Z, Said A. Acute coronary syndrome in young adults from Oman: Results from the gulf registry of acute coronary events. Heart Views. 2010;11(3):93–8.

23. Pasternak RC. Report of the adult treatment panel III: the 2001 national cholesterol education program guidelines on the detection, evaluation and treatment of elevated cholesterol in adults. Cardiol Clin. 2003;21(3):393–89.

24. Jamil G, Jamil M, Alkhazraji H, Haque A, Chedid F, Balasubramanian M, et al. Risk factor assessment of young patients with acute myocardial infarction. Am J Cardiovasc Dis. 2013;3(3):170–4.

25. Shemirani H, Separham KH. The relative impact of smoking or hypertension on severity of premature coronary artery disease. Iranian Red Crescent Medical Journal. 2007;9(4):177–81.

26. Jamil G, Jamil M, Alkhazraji H, Haque A, Chedid F, Balasubramanian M, et al. Risk factor assessment of young patients with acute myocardial infarction. Am J Cardiovasc Dis. 2013;3(3):170–4.

27. Prashanth P, Kadhim S, Ibrahim A-Z, Said A. Acute coronary syndrome in young adults from Oman: Results from the gulf registry of acute coronary events. Heart Views. 2010;11(3):93–8.

28. Sharma M, Ganguly NK. Premature coronary artery disease in Indians and its associated risk factors. Vasc Health Risk Manag. 2008;4(3):217–25.

29. Yamac AH, Uysal O, Ismaeloglu Z, Ertürk M, Celikten M, Bacakasiz A, et al. Premature Myocardial infarction: Genetic variation in SR1 affects disease susceptibility. Cardiol Res Pract. 2019;2019:8921806.

30. Andrews E, León M, Cordero A, Botaya RM, Magan P, Luengo E, et al. Cardiovascular risk factors and lifestyle associated with premature myocardial infarction diagnosis. Rev Esp Cardiol. 2011;64:527–9.

31. Yamac AH, Uysal O, Ismaeloglu Z, Ertürk M, Celikten M, Bacakasiz A, et al. Premature Myocardial Infarction: Genetic Variation in SR1 Affects Disease Susceptibility. Cardiol Res Prat. 2019;2019:8921806.

32. Ranjith N, Begoraro RJ, Rom L. Risk factors and methylenetetrahydrofolate reductase gene polymorphisms in a young South African Indian-born population with acute myocardial infarction. Cardiovasc J Afr. 2003;14(3):127–32.

33. Efeyciou C, Antoniades L, Makri L, Koumas L, Costeas PA, Kyriakou E, et al. Homocysteine levels and MTHFR mutations in young patients with acute myocardial infarction: a case control study. Hellenic J Cardiol. 2012;53(3):189–94.

34. Ambroziauskas M, Kuryłowicz A, Buda A. Increased coagulation factor XIII activity but not genetic variants of coagulation factors is associated with myocardial infarction in young patients. J Thromb Thrombolysis. 2019;48(3):519–27.
35. Silvain J, Penas A, Vignalou JB. FXIII-A Leu34 genetic variant in premature coronary artery disease: a genotype-phenotype case control study. Thromb Haemost. 2011;106(3):51–20.

36. Chen F, Qiao Q, Xu P, Fan B, Chen Z. Effect of Factor XIII-A Val34Leu polymorphism on myocardial infarction risk: A meta-analysis. Clin Appl Thromb Hemost. 2014;20(8):783–92.

37. Reiner AP, Frank MB, Schwartz SM. Evidence of association between prothrombotic gene polymorphisms and the risk of myocardial infarction. Haematologica. 2000;85(1):67–71.

38. Franco RF, Pazin-Filho A, Tavela MH. Factor XIII Val34Leu and the risk of myocardial infarction. Haematologica. 2000;85(1):67–71.

39. Fajer JK. The β fibrinogen gene G-455A polymorphism in Asian subjects with coronary heart disease: A meta-analysis. J Med Hum Genet. 2017;18:19–22.

40. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation. 2003;107(8):1117–22.

41. Rallidis LS, Gialeraki A, Fountoulaki K, Politou M, Sourides V, Travlou A, et al. G-455A polymorphism of β-fibrinogen gene and the risk of premature myocardial infarction in Greece. Thromb Res. 2010;125(1):34–7.

42. Zhang H, Dong P, Yang X, Liu Z. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis. Int J Clin Exp Med. 2014;7(10):3777–88.

43. Eriksson P, Kallin B, van’t Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92:1851–3.

44. Nikolopoulos GK, Bagos PG, Tsangaris I, Tsiara CG, Kopterides P, Vaopoulous A, et al. The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis. Clin Chem Lab Med. 2014;52(7):937–50.

45. Al-Wakeel H, Sevelam N, Khaled M, Abdelbary A. Impact of PAI-1 4G/5G and C>G polymorphisms in acute ST elevation myocardial infarction and stable angina patients: A single center Egyptian study. J Med Hum Genet. 2018;19(4):325–31.

46. Vitanen L, Pihlajamaki J, Halonen P, Lehtonen M, Kareinen A, Lehto S, et al. Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease. Atherosclerosis. 2001;157(1):57–64.

47. Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIb/IIIa A2/A1 polymorphism with myocardial infarction. Am J Cardiol. 2000;86:1000–5.

48. Floyd CN, Mustafa A, Ferro A. The PAI1/A2 polymorphism of glycoprotein IIb/IIIa as a risk factor for myocardial infarction: a meta-analysis. PLoS ONE. 2014;9(7):e101518.

49. Zott RB, Winkelmann BR, Müller C, Boehm BO, Marx W, Scharf RE. Association of polymorphisms of platelet membrane integrins α2β1 (HPA-1b/1a/1b) and α2β3 (O-807TTT) with premature myocardial infarction. J Thromb Haemost. 2005;3(7):1522–9.

50. Chen Y, Dong S, He M, Qi T, Zhu W. Angiotensin-converting enzyme insertion/deletion polymorphism and risk of myocardial infarction in an updated meta-analysis based on 34993 participants. Gene. 2013;522:196–205.

51. Hmimiche W, Idrissi HH, Diakite B, Korchi F, Baghdadi D, Idrissi HTJH, et al. Impact of V/F polymorphism of angiotensin-converting enzyme (ACE) gene on myocardial infarction susceptibility among young Moroccan patients. BMC Research Notes. 2017;10:763.

52. Mehri S, Baudin B, Mahjoub S, Zaroui A, Bénétreau-Burnat B, Mechmeche R, et al. Angiotensin-converting enzyme insertion/deletion gene polymorphism in a Tunisian healthy and acute myocardial infarction population. Genet Test Mol Biomark. 2010;14:85–91.

53. Afshar SM, Firooznia M, Salimi S, Zand H, Hesabi B, Mohhebbi A. Angiotensin- converting enzyme (ACE) I/D polymorphism and risk of coronary artery disease in the Iranian population. Pathophysiology. 2010;17(3):163–7.

54. Ward H, Mitrou PN, Bowman R, Luben R, Wareham N, Khaw KT, et al. APOE Genotype, Lipids, and Coronary Heart Disease Risk. Arch Intern Med. 2009;169(15):1424–9.

55. Eroğlu Z, Selvi N, Kosova B, Biray C, Kumral E, Topcuoglu N, et al. Absence of apolipoprotein B-3500 mutation in Turkish patients with coronary and cerebrovascular atherosclerosis. Anadolu Kardiyol Derg. 2008;8:7–9.

56. Awad NS, El-Tarras AE. Analysis of the APOB R3500Q mutation and APOB 3500T/Q and APOE A2/A1 genotypes in acute ST elevation myocardial infarction—reverse hybridization technique. J Mol Biomark Diagn. 2011;2,2.